Data takes Venclexta closer to wider patient pool in CLL

19 September 2017

The prospect of Venclexta (venetoclax) helping to replace lost revenues at US drugmaker AbbVie (NYSE: ABBV) and Swiss pharma giant Roche (ROG: SIX) rose on Monday with news from the MURANO study.

This Phase III study had met its primary endpoint, it was announced, showing that people with previously treated chronic lymphocytic leukaemia (CLL) who were given Venclexta (venetoclax) and Rituxan (rituximab), lived longer without their disease worsening, compared to bendamustine plus Rituxan.

"This is the first study to show that Venclexta plus Rituxan can help people with this type of leukaemia live significantly longer without their disease worsening compared to a standard-of-care regimen"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK